Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V937 plus pembrolizumab versus pembrolizumab alone in advanced/metastatic melanoma
2019-002034-36Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of coxsackievirus a21 and pembrolizumab in melanoma (3 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Oct 2019; status: completed.
02
Drugs
coxsackievirus a21pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2019-002034-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002034-36.